Cognition Therapeutics (CGTX) Competitors $1.83 +0.09 (+5.17%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.82%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. UPXI, KRRO, AUTL, ATXS, EOLS, ALMS, ETHZ, LRMR, ACIU, and FDMTShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Upexi (UPXI), Korro Bio (KRRO), Autolus Therapeutics (AUTL), Astria Therapeutics (ATXS), Evolus (EOLS), Alumis (ALMS), Flag Ship Acquisition (ETHZ), Larimar Therapeutics (LRMR), AC Immune (ACIU), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Upexi Korro Bio Autolus Therapeutics Astria Therapeutics Evolus Alumis Flag Ship Acquisition Larimar Therapeutics AC Immune 4D Molecular Therapeutics Cognition Therapeutics (NASDAQ:CGTX) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Which has more risk and volatility, CGTX or UPXI? Cognition Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Is CGTX or UPXI more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -86.54%. Upexi's return on equity of -54.33% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -251.23% -130.75% Upexi -86.54%-54.33%-31.28% Does the media favor CGTX or UPXI? In the previous week, Upexi had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Upexi and 2 mentions for Cognition Therapeutics. Upexi's average media sentiment score of 0.92 beat Cognition Therapeutics' score of 0.58 indicating that Upexi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in CGTX or UPXI? 43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 14.4% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 4.4% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer CGTX or UPXI? Cognition Therapeutics presently has a consensus target price of $2.83, indicating a potential upside of 54.83%. Upexi has a consensus target price of $15.50, indicating a potential upside of 157.48%. Given Upexi's higher possible upside, analysts plainly believe Upexi is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has higher valuation and earnings, CGTX or UPXI? Upexi has higher revenue and earnings than Cognition Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$33.97M-$0.67-2.73Upexi$15.81M22.42-$13.68MN/AN/A SummaryUpexi beats Cognition Therapeutics on 7 of the 13 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.93M$3.36B$6.10B$10.46BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-2.7322.7785.5227.36Price / SalesN/A486.54609.44137.64Price / CashN/A46.7037.4661.86Price / Book5.9010.5512.396.81Net Income-$33.97M-$52.58M$3.32B$276.80M7 Day Performance-6.15%0.09%0.57%0.42%1 Month Performance13.66%15.61%10.53%7.86%1 Year Performance308.66%15.13%72.40%41.24% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.4381 of 5 stars$1.83+5.2%$2.83+54.8%+334.7%$127.93MN/A-2.7320Positive NewsUPXIUpexi2.4472 of 5 stars$7.70+3.5%$15.50+101.3%+132.4%$438.13M$15.81M0.00130Positive NewsAnalyst ForecastGap DownKRROKorro Bio1.8186 of 5 stars$43.70-5.5%$86.83+98.7%+29.2%$434.05M$2.27M-4.4870Analyst ForecastAUTLAutolus Therapeutics3.421 of 5 stars$1.56-3.1%$9.12+484.6%-59.6%$428.49M$10.12M-1.86330Gap UpATXSAstria Therapeutics2.1855 of 5 stars$7.69+2.3%$29.50+283.6%+3.7%$424.39MN/A-3.8330Trending NewsAnalyst DowngradeEOLSEvolus4.029 of 5 stars$6.43-1.1%$21.25+230.5%-60.4%$420.45M$277.94M-6.56170Analyst ForecastALMSAlumis3.5648 of 5 stars$4.12+2.5%$20.17+389.5%-56.7%$418.34MN/A0.00N/APositive NewsETHZFlag Ship AcquisitionN/A$2.55+0.8%N/AN/A$416.01MN/A-0.177News CoverageStock SplitGap DownLRMRLarimar Therapeutics2.9605 of 5 stars$4.81-1.2%$16.71+247.5%-42.9%$403.13MN/A-3.0830ACIUAC Immune1.7921 of 5 stars$3.54-11.3%$10.00+182.5%-4.1%$400.64M$28.92M-6.10140Positive NewsHigh Trading VolumeFDMT4D Molecular Therapeutics2.4841 of 5 stars$8.40-1.8%$30.40+261.9%+12.0%$399.31M$40K-2.38120 Related Companies and Tools Related Companies Upexi Competitors Korro Bio Competitors Autolus Therapeutics Competitors Astria Therapeutics Competitors Evolus Competitors Alumis Competitors Flag Ship Acquisition Competitors Larimar Therapeutics Competitors AC Immune Competitors 4D Molecular Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
